前臨床CRO（開発業務受託機関）市場の2030年までの予測： モデルタイプ別、サービス別、動物モデル別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の前臨床CRO（開発業務受託機関）市場は2023年に49億9,000万米ドルを占め、予測期間中のCAGRは9.5％で成長し、2030年には94億2,000万米ドルに達すると予測されています。

前臨床CRO（開発業務受託機関）は、製薬およびバイオテクノロジー業界における専門サービスプロバイダーであり、臨床試験に入る前の実験的な医薬品や治療法に関する調査や試験を実施します。新規化合物の安全性、有効性、危険性を評価するため、前臨床CROは幅広いサービスを提供しています。さらに、前臨床CROの知識とリソースは、重要な情報と規制上のサポートを提供し、規制と業界の規範を遵守することで、医薬品開発の最適化を支援します。

IFPMAの2021年版報告書によると、国際的なバイオ医薬品産業の年間研究開発費は、航空宇宙・防衛産業の7.3倍、化学産業の6.5倍、ソフトウェア・コンピュータサービス産業の1.5倍となっています。

世界化の進展

CROは国際的なビジネスであり、製薬企業やバイオテクノロジー企業に、幅広いリソースや知識、複数の法域における規制ルートへのアクセスを提供しています。規制上のメリット、多様な患者集団、新興国市場を活用することで、企業はグローバリゼーションを通じて医薬品開発戦略を最適化することができます。さらに、協力とイノベーションを促進し、新薬の上市までの時間と効率を加速させることで、ヘルスケアの成果を向上させ、最先端の治療薬への一般市民のアクセスを改善することができます。

高コスト

厳しい規制を遵守し、品質基準を維持する必要があるため、出費がかさみます。前臨床研究を適切に実施するために、CROは最先端の施設、機械、優秀なスタッフに多額の資金を投資しなければならないです。激しい競合はCROにとってよくあることで、市場競争や事業開拓のイニシアチブの価格が上昇します。さらに、小規模または新設のCROは、こうした法外なコストのために市場参入が困難となる可能性があり、市場成長の妨げとなります。

技術の進歩

製薬企業やバイオテクノロジー企業は、高度な技術を駆使して医薬品開発に関する適切な判断を下すことができます。CROは、開発リスクを低減し、有望な医薬品候補の特定を迅速化し、新規治療法の一般的な品質と安全性を向上させるために、この特定の知識を使用しています。さらに、CROはその専門性と経験から、厳しい政府規制の中で医薬品開発とイノベーションを推進する上で有利な協力者となり、市場規模を拡大させています。

厳しい規制環境

この領域で事業を展開するCROは、複雑な規制の枠組みを乗りこなす上で課題に直面し、コンプライアンスコストの増加やプロジェクトスケジュールの遅延につながる可能性があります。厳しい規制環境は、製薬企業やバイオテクノロジー企業がCROパートナーを選定する際の意思決定プロセスにも影響を与えます。さらに、規制の負荷は承認プロセスの長期化や査察の強化につながり、CROが実施する前臨床研究の全般的な有効性とペースに影響を与えます。このような不利な環境はイノベーションを阻害し、前臨床研究サービスの利用可能性を低下させ、市場の拡大を阻害します。

COVID-19の影響

COVID-19の流行は、前臨床CRO（開発業務受託機関）市場に顕著な悪影響を及ぼしています。延期または中止された前臨床試験の数により、CROサービスに対するニーズが減少しました。パンデミックによる財政不安は研究開発への投資を減少させ、前臨床試験のアウトソーシングのために確保される資金に影響を及ぼしています。さらに、パンデミックによる景気後退と先行き不透明感により、一部の顧客は前臨床試験を延期または中止し、CROの収益と成長見通しに影響を与え、この市場をさらに阻害しています。

予測期間中、毒性試験分野が最大となる見込み

毒性試験分野が最大のシェアを占めると推定されます。毒性学に特化したCROは、厳しい規制基準を満たすために潜在的な医薬品を徹底的に評価することで、バイオテクノロジーや製薬企業に重要なサービスを提供しています。これらの試験は、化学物質がさまざまな生物学的システムにどのような影響を与えるかを評価することで、有害な反応や投与量を発見するのに役立ちます。そのため、開発リスクを最小限に抑え、規制当局の承認を迅速化し、医薬品の安全性を保証することで、公衆衛生と医薬品開発イニシアチブの成功を守り、このセグメントの成長を後押ししています。

患者由来異種移植片（PDX）セグメントは予測期間中に最も高いCAGRが見込まれる

患者由来の異種移植片（PDX）セグメントは、予測期間中にCAGRが最も高くなると予想されます。これは、患者の腫瘍組織を免疫不全マウスに移植して患者の腫瘍環境を再現するPDXモデルによるものです。これらのモデルは、薬剤候補がより臨床的に適切な環境で評価される場合、ヒト試験で成功する可能性が高くなります。さらに、PDX CROはオーダーメイド医療の知見を提供し、特定の患者に対する治療を可能にします。PDX市場は、プレシジョン・メディシンの重要性が高まっていることから、効率的で的を絞ったがん治療をさらに開発するために不可欠であり、このセグメントの拡大を牽引しています。

最大のシェアを占める地域

アジア太平洋地域は、製薬企業とCRO間の円滑なデータ交換と協力を促進する統合プラットフォームの成長により、予測期間中に最大の市場シェアを獲得しました。Covance Inc.、Medpace Holdings, Inc.、MPI Research、Eurofins Scientificなどの主要企業は、国際共同研究のための魅力的な環境を提供し、世界の製薬・バイオテクノロジー産業の発展に貢献しています。さらに、政府支援の拡大、規制の調和、データ処理のためのハイスループットスクリーニング、機械学習、人工知能などの技術的進歩がこの地域の拡大を後押ししています。

CAGRが最も高い地域：

北米は、医薬品開発の前臨床段階において製薬企業やバイオテクノロジー企業を支援する上で極めて重要な役割を担っていることから、予測期間中に最も高いCAGRを記録すると予想されます。米国、カナダ、メキシコ地域は、強固なインフラ、最先端技術、高度に熟練した労働力を特徴としています。これらの地域には、薬理学、毒物学、生物学的分析、その他薬事承認に不可欠な様々な前臨床試験が含まれます。さらに、この地域のCROは、恵まれた規制環境と学術機関との連携から恩恵を受け、技術革新と専門知識を育み、この地域の成長を後押ししています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の前臨床CRO（開発業務受託機関）市場：モデルタイプ別

• 患者由来異種移植片（PDX）
• 患者由来オルガノイド（PDO）

第6章 世界の前臨床CRO（開発業務受託機関）市場：サービス別

• 安全性薬理学
• 生物分析および薬物代謝および薬物動態（DMPK）研究
  • インビトロ薬物動態学（PK）
  • 生体内薬物動態学（PK）
• 毒性試験
• 化学
  • 計算化学
  • 医薬品化学
• 化合物の管理
  • プロセスの研究開発
  • カスタム合成
  • その他の複合管理
• その他のサービス

第7章 世界の前臨床CRO（開発業務受託機関）市場：動物モデル別

• 大型動物モデル
• 小動物モデル

第8章 世界の前臨床CRO（開発業務受託機関）市場：エンドユーザー別

• 政府および学術機関
• 医療機器企業
• バイオ医薬品企業
• その他のエンドユーザー

第9章 世界の前臨床CRO（開発業務受託機関）市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Crown Bioscience
• Eurofins Scientific
• Laboratory Corporation of America, Inc.
• PRA Health Sciences, Inc.
• Intertek Group Plc（IGP）
• Wuxi AppTec
• SGS SA（SGS）
• Medpace, Inc.
• Pharmaceutical Product Development（PPD）, LLC
• Charles River Laboratories International, Inc.
• PPD（Thermo Fisher Scientific, Inc.）
• WuXi AppTec, Inc.（WAI）

List of Tables

• Table 1 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
• Table 3 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
• Table 4 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
• Table 5 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
• Table 6 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
• Table 7 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
• Table 8 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 9 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 10 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
• Table 11 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
• Table 12 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
• Table 13 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
• Table 14 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
• Table 15 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
• Table 16 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
• Table 17 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
• Table 18 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
• Table 19 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
• Table 20 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
• Table 21 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
• Table 22 Global Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
• Table 23 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
• Table 24 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
• Table 25 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
• Table 26 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 27 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
• Table 28 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
• Table 29 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
• Table 30 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
• Table 31 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
• Table 32 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
• Table 33 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
• Table 34 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 35 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 36 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
• Table 37 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
• Table 38 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
• Table 39 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
• Table 40 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
• Table 41 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
• Table 42 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
• Table 43 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
• Table 44 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
• Table 45 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
• Table 46 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
• Table 47 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
• Table 48 North America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
• Table 49 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
• Table 50 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
• Table 51 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
• Table 52 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 53 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
• Table 54 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
• Table 55 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
• Table 56 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
• Table 57 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
• Table 58 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
• Table 59 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
• Table 60 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 61 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 62 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
• Table 63 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
• Table 64 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
• Table 65 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
• Table 66 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
• Table 67 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
• Table 68 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
• Table 69 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
• Table 70 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
• Table 71 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
• Table 72 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
• Table 73 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
• Table 74 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
• Table 75 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
• Table 76 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
• Table 77 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
• Table 78 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 79 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
• Table 80 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
• Table 81 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
• Table 82 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
• Table 83 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
• Table 84 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
• Table 85 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
• Table 86 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 87 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 88 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
• Table 89 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
• Table 90 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
• Table 91 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
• Table 92 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
• Table 93 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
• Table 94 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
• Table 95 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
• Table 96 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
• Table 97 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
• Table 98 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
• Table 99 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
• Table 100 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
• Table 101 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
• Table 102 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
• Table 103 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
• Table 104 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 105 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
• Table 106 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
• Table 107 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
• Table 108 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
• Table 109 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
• Table 110 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
• Table 111 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
• Table 112 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 113 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 114 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
• Table 115 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
• Table 116 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
• Table 117 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
• Table 118 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
• Table 119 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
• Table 120 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
• Table 121 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
• Table 122 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
• Table 123 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
• Table 124 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
• Table 125 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
• Table 126 South America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
• Table 127 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
• Table 128 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
• Table 129 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
• Table 130 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 131 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
• Table 132 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
• Table 133 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
• Table 134 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
• Table 135 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
• Table 136 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
• Table 137 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
• Table 138 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 139 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
• Table 140 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
• Table 141 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
• Table 142 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
• Table 143 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
• Table 144 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
• Table 145 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
• Table 146 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
• Table 147 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
• Table 148 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
• Table 149 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
• Table 150 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
• Table 151 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
• Table 152 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
• Table 153 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
• Table 154 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
• Table 155 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
• Table 156 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Preclinical Contract Research Organization (CRO) Market is accounted for $4.99 billion in 2023 and is expected to reach $9.42 billion by 2030 growing at a CAGR of 9.5% during the forecast period. A Preclinical Contract Research Organization (CRO) is a specialized service provider in the pharmaceutical and biotechnology industry that conducts research and testing on experimental drugs and therapies before they enter clinical trials. To evaluate the safety, efficacy, and possible dangers associated with novel compounds, preclinical CROs provide a broad range of services. Furthermore, their knowledge and resources aid pharmaceutical businesses in optimizing drug development by offering vital information and regulatory support and by providing adherence to regulatory and industry norms.

According to the IFPMA's 2021 report, the annual R&D spending by the international biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Increase in globalization

CROs are international businesses that provide pharmaceutical and biotech firms with access to a wide range of resources, knowledge, and regulatory routes in several jurisdictions. By taking advantage of regulatory benefits, diversified patient populations, and developing markets, corporations can optimize their drug development strategy through globalization. Additionally, it improves healthcare outcomes and public access to cutting-edge therapeutics by encouraging cooperation and innovation and accelerating the time and efficiency of bringing new drugs to market.

Restraint:

High cost

The need to adhere to stringent regulatory regulations and uphold quality standards increases expenditures. To properly undertake preclinical research, CROs must invest a significant amount of money in cutting-edge facilities, machinery, and highly qualified staff. Intense competition is a common occurrence for CROs, which raises the price of marketing and business development initiatives. In addition, smaller or newly established CROs may find it difficult to enter the market due to these exorbitant costs, which thereby hinder market growth.

Opportunity:

Technological advancements

Pharmaceutical and biotech businesses may make well-informed judgments on drug development with the help of their advanced technologies, which enables them to provide reliable and efficient preclinical testing and data analysis. CROs use this specific knowledge to lower development risks, speed up the identification of promising drug candidates, and improve the general quality and safety of novel treatments. Furthermore, because of their specialization and experience, CROs are advantageous collaborators for promoting drug development and innovation in a tough, government-regulated setting thereby driving this market size.

Threat:

Stringent regulatory environment

CROs operating in this space encounter challenges in navigating the intricate regulatory frameworks, leading to increased compliance costs and potential delays in project timelines. The stringent regulatory environment also influences the decision-making process of pharmaceutical and biotechnology companies when selecting CRO partners. Furthermore, the regulatory load results in longer approval processes and more inspection, affects the general effectiveness and pace of preclinical research carried out by CROs. This unfavourable environment inhibits innovation, lowers the availability of preclinical research services, and thereby impedes this market expansion.

COVID-19 Impact

The COVID-19 pandemic has had a notable negative impact on the preclinical contract research organization (CRO) market. The number of preclinical studies that were postponed or cancelled resulted in a decline in the need for CRO services. The pandemic's financial insecurity has resulted in decreased investment in research and development, which has an effect on the money set aside for preclinical study outsourcing. Furthermore, the pandemic-induced economic downturn and uncertainty prompted some clients to postpone or cancel preclinical projects, impacting the revenue and growth prospects of CRO and further impeding this market.

The toxicology testing segment is expected to be the largest during the forecast period

The toxicology testing segment is estimated to hold the largest share. Toxicology-focused CROs offer vital services to biotech and pharmaceutical firms by thoroughly assessing potential drugs in order to satisfy strict regulatory standards. These tests help discover harmful reactions and dosage levels by assessing how chemicals affect different biological systems. Therefore, it protects public health and the success of drug development initiatives by minimizing development risks, expediting regulatory approvals, and guaranteeing the safety of pharmaceutical goods, which thereby boosts this segment's growth.

The patient derived xenograft (PDX) segment is expected to have the highest CAGR during the forecast period

The patient derived xenograft (PDX) segment is anticipated to have highest CAGR during the forecast period due to the tumor tissues from patients being transplanted into immunodeficient mice in PDX models to replicate the tumor environment of the patient. These models show a greater chance of success in human trials when drug candidates are evaluated in a more clinically appropriate setting. Furthermore, customized medicine insights are provided by PDX CROs, enabling treatmentsfor specific patients. The PDX market is essential for further developing efficient and targeted cancer treatments because of the growing significance of precision medicine, thereby driving this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the growth of integrated platforms that facilitate smooth data exchange and cooperation between pharmaceutical corporations and CROs. Key players such as Covance Inc., Medpace Holdings, Inc., MPI Research, and Eurofins Scientific offer a compelling environment for international collaborations and are establishing themselves in advancing the global pharmaceutical and biotechnology industries. Additionally, growing government support, regulatory harmonization, and technological advancements such as high-throughput screening, machine learning, and artificial intelligence for data processing drive this region's expansion.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to its pivotal role in supporting pharmaceutical and biotechnology companies in the preclinical phase of drug development. The United States, Canada, and Mexico regions are characterized by a robust infrastructure, cutting-edge technology, and a highly skilled workforce. They include pharmacology, toxicology, bioanalysis, and various other preclinical studies essential for regulatory approval. Furthermore, the region's CROs benefit from a favorable regulatory environment and collaboration with academic institutions, fostering innovation and expertise that are propelling this region's growth.

Key players in the market:

Some of the key players in the Preclinical Contract Research Organization (CRO) Market include Crown Bioscience, Eurofins Scientific, Laboratory Corporation of America, Inc., PRA Health Sciences, Inc., Intertek Group Plc (IGP), Wuxi AppTec, SGS SA (SGS), Medpace, Inc., Pharmaceutical Product Development (PPD), LLC, Charles River Laboratories International, Inc., PPD (Thermo Fisher Scientific, Inc.) and WuXi AppTec, Inc. (WAI).

Key Developments:

In November 2023, Intertek, announced the launch of iCare in Turkiye, one of its most successful markets. iCare is an innovative one-stop digital portal providing textile manufacturers with a pioneering solution that enables seamless management and monitoring of their testing processes from start to finish.

In October 2023, SGS is signed an agreement to divest its US powertrain testing operations as part of its strategic portfolio evolution to Columbia River Partners, a private equity firm focused on the industrials, business services and IT services sectors, headquartered in California.

In September 2023, Intertek, proudly announced the integration of advanced PhotonAssay technology into its Minerals laboratory facility in Tarkwa, Ghana. With a legacy of excellence and a commitment to innovation, Intertek Minerals aims to revolutionise gold industry support in West Africa through the implementation of this groundbreaking technology.

Model Types Covered:

• Patient Derived Xenograft (PDX)
• Patient Derived Organoid (PDOs)

Services Covered:

• Safety Pharmacology
• Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
• Toxicology Testing
• Chemistry
• Compound Management
• Other Services

Animal Models Covered:

• Large Animal Model
• Small Animal Model

End Users Covered:

• Government and Academic Institutes
• Medical Device Companies
• Biopharmaceutical Companies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Preclinical Contract Research Organization (CRO) Market, By Model Type

• 5.1 Introduction
• 5.2 Patient Derived Xenograft (PDX)
• 5.3 Patient Derived Organoid (PDOs)

6 Global Preclinical Contract Research Organization (CRO) Market, By Service

• 6.1 Introduction
• 6.2 Safety Pharmacology
• 6.3 Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
  • 6.3.1 In vitro Pharmacokinetics (PK)
  • 6.3.2 In-vivo Pharmacokinetics (PK)
• 6.4 Toxicology Testing
• 6.5 Chemistry
  • 6.5.1 Computation Chemistry
  • 6.5.2 Medicinal Chemistry
• 6.6 Compound Management
  • 6.6.1 Process R&D
  • 6.6.2 Custom Synthesis
  • 6.6.3 Other Compound Managements
• 6.7 Other Services

7 Global Preclinical Contract Research Organization (CRO) Market, By Animal Model

• 7.1 Introduction
• 7.2 Large Animal Model
• 7.3 Small Animal Model

8 Global Preclinical Contract Research Organization (CRO) Market, By End User

• 8.1 Introduction
• 8.2 Government and Academic Institutes
• 8.3 Medical Device Companies
• 8.4 Biopharmaceutical Companies
• 8.5 Other End Users

9 Global Preclinical Contract Research Organization (CRO) Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Crown Bioscience
• 11.2 Eurofins Scientific
• 11.3 Laboratory Corporation of America, Inc.
• 11.4 PRA Health Sciences, Inc.
• 11.5 Intertek Group Plc (IGP)
• 11.6 Wuxi AppTec
• 11.7 SGS SA (SGS)
• 11.8 Medpace, Inc.
• 11.9 Pharmaceutical Product Development (PPD), LLC
• 11.10 Charles River Laboratories International, Inc.
• 11.11 PPD (Thermo Fisher Scientific, Inc.)
• 11.12 WuXi AppTec, Inc. (WAI)